Gegenanzeigen · Aerinaze
Aerinaze 2.5 mg/120 mg modified-release tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-117629 · Präparat HOS-094665
Aerinaze is also contraindicated in patients with: • narrow-angle glaucoma, • urinary retention, • cardiovascular diseases such as ischaemic heart disease and tachyarrhythmia, • severe hypertension or uncontrolled hypertension, • hyperthyroidism, • a history of haemorrhagic stroke or with risk factors which could increase the risk of haemorrhagic stroke. This is due to the alpha-mimetic activity of pseudoephedrine sulphate in combination with other vasoconstrictors such as bromocripitine, pergolide, lisuride, cabergoline, ergotamine, dihydroergotamine or any other decongestant medicinal product used as a nasal decongestant, either by oral route or by nasal route (phenylpropanolamine, phenylephrine, ephedrine, oxymetazoline, naphazoline…), • severe acute or chronic kidney disease/renal failure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenylephrine (HOS-117634) ephedrine (HOS-113309) phenylpropanolamine (HOS-117633) pseudoephedrine (HOS-113310) lisuride (HOS-117631) naphazoline (HOS-117637) oxymetazoline (HOS-117636) ergotamine (HOS-086154) cabergoline (HOS-117632) pergolide (HOS-090552) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T02:00:00Z · SHA-256 5f8f717272c7b0715f3f3850df32a9fdf827287c0fbb36ceed60bbd0a24f3b53 · Passage fcb9b963272eb2ba02dbe1ab67e07b701804c4673b3a9474d65e6cd568330535 · Zeichen 357–1219 im Abschnitt